RecruitingNCT06026345

Affera Global Registry

The Affera Global Registry is a Prospective, Global, Multi-center, Observational Post-market Registry (PMR)


Sponsor

Medtronic Cardiac Ablation Solutions

Enrollment

540 participants

Start Date

Dec 22, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The Affera Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to describe clinical performance and safety data in a broad patient population treated with the Affera Platform.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Subject is ≥ 18 years of age or minimum age as required by local regulations
  • Planned procedure using the commercially available Affera Platform
  • Willing and able to comply with study requirements and give IC (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements

Exclusion Criteria1

  • Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager

Interventions

DEVICEAffera Platform

A cardiac ablation will be performed using the Affera Platform


Locations(12)

Universitair Ziekenhuis Brussel

Brussels, Belgium

IKEM - Institut Klinické a Experimentální Medicíny

Prague, Czechia

Nemocnice Na Homolce

Prague, Czechia

Hôpital Haut-Lévêque - CHU de Bordeaux

Bordeaux, France

Clinique Pasteur

Toulouse, France

Charité Universitätsmedizin Berlin, DHZC - Campus Charité Mitte

Berlin, Germany

MVZ CCB Frankfurt und Main Taunus GbR

Frankfurt, Germany

Universitäres Herzzentrum

Hamburg, Germany

Beacon Hospital

Dublin, Ireland

Inselspital - Universitätsspital Bern

Bern, Switzerland

Royal Papworth Hospital NHS Foundation Trust

Cambridge, United Kingdom

Imperial College Healthcare NHS Trust - Hammersmith Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06026345


Related Trials